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Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic bunyavirus of the genus Phlebovirus and a
serious human and veterinary pathogen. RVFV contains a three-segmented RNA genome, which is comprised
of the large (L), medium (M), and small (S) segments. The proteins that are essential for genome replication
are encoded by the L and S segments, whereas the structural glycoproteins are encoded by the M segment. We
have produced BHK replicon cell lines (BHK-Rep) that maintain replicating L and S genome segments.
Transfection of BHK-Rep cells with a plasmid encoding the structural glycoproteins results in the efficient
production of RVFV replicon particles (RRPs). To facilitate monitoring of infection, the NSs gene was replaced
with an enhanced green fluorescent protein gene. RRPs are infectious for both mammalian and insect cells but
are incapable of autonomous spreading, rendering their application outside biosafety containment completely
safe. We demonstrate that a single intramuscular vaccination with RRPs protects mice from a lethal dose of
RVFV and show that RRPs can be used for rapid virus neutralization tests that do not require biocontainment
facilities. The methods reported here will greatly facilitate vaccine and drug development as well as funda-
mental studies on RVFV biology. Moreover, it may be possible to develop similar systems for other members
of the bunyavirus family as well.
The family Bunyaviridae is divided into five genera, of which
four (Orthobunyavirus, Nairovirus, Phlebovirus, and Hantavirus)
include numerous virus species capable of causing severe dis-
ease in both animals and humans. Well-known examples are
hantavirus (HTNV; genus Hantavirus), Crimean-Congo hem-
orrhagic fever virus (CCHFV; genus Nairovirus), and Rift Val-
ley fever virus (RVFV; genus Phlebovirus). Although RVFV,
HTNV, and CCHFV cause severe disease with high fatality
rates, no vaccines are available for the prevention of these
diseases in humans, and no antiviral agents are registered for
postexposure treatment. The development of such control
tools is complicated by the fact that these viruses must be
handled under high-level biosafety containment conditions.
In the veterinary field, RVFV is the most feared bunyavirus.
The mortality rate in adult ruminants can be up to 20%,
whereas fatality rates in unborn and young animals can be even
more dramatic, approaching 100% (16, 17). The human fatality
rate is historically estimated to be below 1%, although consid-
erably higher mortality rates have been reported (1, 2, 19).
RVFV is currently largely confined to the African continent
and the Arabian Peninsula, but mosquitoes capable of trans-
mitting RVFV are not restricted to these areas (33, 43, 44).
This explains the growing concern for RVFV incursions into
previously unaffected areas, including Europe, Australasia, and
the Americas (9, 10, 12, 22, 37).
Like other bunyavirus family members, RVFV contains a
three-segmented RNA genome, comprising a large (L), me-
dium (M), and small (S) segment (21). The L segment encodes
the viral RNA polymerase. The M segment contains five
in-frame start codons which give rise to the structural gly-
coproteins Gn and Gc and two major nonstructural proteins,
referred to as NSm1 and NSm2 (Fig. 1). The S segment
encodes the nonstructural NSs protein and the nucleocapsid
(N) protein. The NSs protein suppresses host innate im-
mune responses and was shown to be the primary virulence
factor of the virus (5, 13, 25, 34).
The recent establishment of a reverse-genetics system for
RVFV has provided important new insights into its biology (7,
12, 23, 26). A few years after the first successful rescue of
RVFV from cloned cDNA, the packaging of a reporter mini-
genome into virus-like particles (VLPs) was reported (24). The
VLPs were produced by transient expression of the NSm, Gn,
Gc, N, and L proteins in the presence of the reporter minige-
nome. In this system, the N and L proteins produced from
protein expression plasmids facilitate replication of the mini-
genome. The minigenome is subsequently packaged by the
structural glycoproteins into so-called infectious VLPs (iVLPs),
which are able to transport the RNA to receiving cells.
Whereas primary transcription occurs in these cells, replication
of the minigenome and high-level reporter gene expression
depend on de novo production of N and L proteins from
transfected plasmids (24).
A recent study reported the copackaging of the M and S
genome segments into VLPs (42). Packaging of the L genome
segment into VLPs was not accomplished in these studies, and
it was proposed that the M genome segment, either alone or in
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a coordinated action with the S segment, is essential for pack-
aging of the L segment. Here, we describe efficient methods for
producing large amounts of virus particles that contain both S
and L genome segments and thereby demonstrate that the M
segment is not essential for this process. By virtue of the L and
S genome segments, the particles are capable of autonomous
genome replication and high-level gene expression. However,
since the M genome segment is absent, the particles are inca-
pable of autonomous spread. The so-called RVFV replicon
particles (RRPs) were produced to titers exceeding 107 infec-
tious particles/ml.
We propose that RVFV RRPs optimally combine the effi-
cacy of live vaccines with the safety of inactivated vaccines and
support this notion by demonstrating that a single intramuscu-
lar vaccination with 106 RRPs completely protects mice from a
lethal dose of RVFV. We also show that RRPs can be used for
rapid virus neutralization tests that do not require biosafety
containment facilities.
The methods described here will greatly facilitate both
fundamental and applied research on RVFV and can po-
tentially be established for other members of the bunyavirus
family as well.
MATERIALS AND METHODS
Cells and growth conditions. BSR-T7/5 cells were kindly provided by K.
Conzelmann (Max von Pettenkofer-Institut, Munich, Germany). BSR-T7/5 cells,
BHK cells, and derivatives were grown in Glasgow minimum essential medium
(GMEM; Invitrogen, Carlsbad, CA) supplemented with 4% tryptose phosphate
broth (Invitrogen), 1% minimum essential medium nonessential amino acids
(MEM NEAA, Invitrogen), and 5 to 10% fetal bovine serum (FBS; Bodinco,
Alkmaar, The Netherlands). For maintenance of stable cell lines, Geneticin
(G-418; Promega, Madison, WI) was used at a concentration of 1 mg/ml. For the
production of RRPs for the vaccination-challenge trial, cells were grown in
Optimem (Invitrogen) supplemented with 2% FBS. Cells were grown at 37°C
and 5% CO2. Drosophila (S2) cells were grown in Schneider’s medium (Invitro-
gen) at 28°C. Aedes albopictus C6/36 cells were grown in Dulbecco’s modified
Eagle medium (Invitrogen) supplemented with 10% FBS at 28°C and 5% CO2.
Plasmids and viruses. Plasmid pCIneo-GnGc contains the open reading frame
of the M segment of RVFV strain 35/74, starting at the fourth methionine codon.
The Gn/Gc-coding sequence was codon optimized for optimal expression in
mammalian cells and synthesized by the GenScript Corporation (Piscataway,
NJ). Plasmids pCIneo-M and pCAGGS-M contain cDNA of the authentic RNA
sequence of the M segment starting at the first methionine codon. Expression of
genes from pCIneo is controlled by a cytomegalovirus (CMV) immediate-early
enhancer/promoter, whereas the expression of genes from the pCAGGS plasmid
is controlled by a CMV immediate enhancer/ß-actin (CAG) promoter (36).
RVFV strain 35/74 was isolated from a liver of a sheep that died during an
RVFV outbreak in the Free State province of South Africa in 1974 (3). The virus
was passaged four times in mouse brain and three times in BHK cells. Amplifi-
cation of the genome was performed by a one-step RT-PCR using primers
previously described by Bird et al. (8). PCR products were purified from agarose
gels and used for GS FLX sequencing at Inqaba Biotec (Pretoria, South Africa)
essentially as described previously (40). The consensus sequences corresponding
to each genome segment were synthesized and cloned in pUC57, a standard
cloning vector of the GenScript Corporation (Piscataway, NJ). pUC57-L,
pUC57-M, and pUC57-S encode the RVFV L, M, and S genome segments,
respectively, in antigenomic orientation. The complete sequence of the L, M, and
S genome sequences can be found in GenBank under the accession numbers
JF784386, JF784387, and JF784388, respectively. Of note, the cDNA of the M
segment present in plasmid pUC57-M contains a silent A-to-G mutation at
position 182. The transcription plasmids each contain a complete copy of the
viral RNA segments and are flanked by a minimal T7 promoter and a hepatitis
delta virus ribozyme sequence. In pUC57-S-eGFP, the NSs gene is replaced by
the gene encoding enhanced green fluorescent protein (eGFP) (Fig. 1, inset).
Rescue of recombinant RVFV strain 35/74. BSR-T7/5 cells were seeded in
six-well plates and were cotransfected with 1 g of plasmids pUC57-L,
pUC57-M, and pUC57-S using jetPEI transfection reagent according to the
instructions of the manufacturer (Polyplus-transfection SA, Illkirch, France).
After 6 days of incubation, the medium was collected and used for virus titration
on BHK cells.
Alternatively, BHK cells were infected with a recombinant fowlpox virus
(FPV) that produces T7 polymerase (15, 18). This virus, named fpEFLT7pol
(referred to here as FP-T7), was previously kindly provided by the Institute for
Animal Health (IAH, Compton, United Kingdom). After incubation with FP-T7
for 1 h and recovery for another hour, the cells were treated as described for
BSR-T7/5 cells. Virus titers were determined as 50% tissue culture infective
doses (TCID50) using BHK cells and were calculated using the Spearman-Ka¨rber
method (27, 41).
Production of RRPs. For the production of RRPs using the three-plasmid
system, BHK or BHK-GnGc cells were seeded in six-well plates and incubated
with FP-T7 for 1.5 to 2 h at 37°C. Medium was refreshed, and cells were allowed
to recover for 1 h. Cells were subsequently transfected with 600 ng each of
pUC57-L, pUC57-S-eGFP, and pCAGGS-M. The medium was refreshed the
next day. Supernatants were harvested after 72 h, precleared by low-speed
centrifugation at room temperature, and stored at 4°C until further use.
For the production of RRPs using the one-plasmid system, HEK293T cells
were seeded in six-well plates and infected with RRPs at a multiplicity of infec-
tion (MOI) of 3. Three days later, the cells were passaged in the wells of a 6-well
plate and transfected with 1 g of pCAGGS-M. RRPs were collected from the
culture medium at 72 h posttransfection. Alternatively, BHK-Rep cells were
transfected with pCAGGS-M, and RRPs were collected at different time points.
The titers of RRPs were determined by TCID50 assays using BHK cells and
were calculated using the Spearman-Ka¨rber method (27, 41). Infectivity was
detected by monitoring eGFP expression using a Zeiss fluorescence microscope.
For the production of RRPs for vaccination of mice, BHK-Rep cells were
grown in Optimem supplemented with 2% FBS. The cells were transfected with
pCAGGS-M, and after 24 h the medium was collected. The RRPs in the col-
lected medium were concentrated using Amicon filters (Millipore, Billerica,
MA) and subsequently diluted in PBS to a titer of 107.3 TCID50/ml.
Northern blotting. RNA probes were prepared by T7-based in vitro transcrip-
tion in the presence of digoxigenin-11-UTP according to the instructions pro-
vided with the DIG Northern starter kit (Roche, Woerden, The Netherlands).
Templates for in vitro transcription were produced by PCR using cDNA of the S,
M, and L segments as the template and dedicated primers containing the T7
promoter sequence. The S probe comprised nucleotides 1 to 378 of the S
FIG. 1. RVFV genome organization and expression strategy of the
M genome segment. (A) Schematic representation of the RVFV small
(S), medium (M), and large (L) genome segments in antigenomic
orientation. (Inset) S-based minigenome containing the eGFP gene
used in this work. (B) Coding strategy of the M genome segment. The
mRNA encoded by the M segment is translated into a polyprotein that
is processed into the NSm1, NSm2, Gn, and Gc proteins.
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segment, the M probe comprised nucleotides 3545 to 3885, and the L probe
comprised nucleotides 1 to 320 (all in antigenomic-sense orientation).
Viral RNA of recombinant RVFV strain 35/74 (r35/74) was extracted with a
High Pure viral RNA kit (Roche) according to the instructions of the manufac-
turer. RVFV RNA from the BHK-Rep and BHK-Rep2 cells was extracted using
the RNeasy kit according to the instructions of the manufacturer (Qiagen,
Hilden, Germany). RNA was separated by electrophoresis using the glyoxal-
dimethyl sulfoxide system provided with the Northern-Max-Gly kit (Ambion,
Austin, TX). Size-fractionated RNA was transferred by blotting onto positively
charged nylon membranes (Roche) using the transfer buffer of the Northern-
Max-Gly kit. RNA was fixed on the membrane by baking at 80°C for 30 min.
Hybridization of digoxigenin (DIG)-labeled RNA probes was performed using
UltraHyb hybridization buffer and wash solutions according to the recommen-
dations of the manufacturer (Ambion).
Detection of hybridized probes was performed using the DIG Northern starter
kit (Roche) according to the manufacturer’s protocol. Briefly, blots were incu-
bated in blocking solution for 30 min and subsequently incubated with alkaline
phosphatase-conjugated anti-DIG antibody for 30 min, followed by washing
twice in washing buffer. After equilibration in detection buffer, blots were incu-
bated with the chemiluminescent substrate supplied by the DIG kit (CDP-Star)
and exposed to X-ray films (Amersham Hyperfilm).
Polyacrylamide gel electrophoresis (PAGE) and Western blotting. Proteins
were separated in bis-Tris gradient gels (Invitrogen) and analyzed by Western
blotting as described previously (28). For Western blot analysis of Gn and Gc,
rabbit peptide antisera were used (20). Monoclonal antibody (MAb) F1D11
(kindly provided by Alejandro Brun, CISA-INIA, Madrid, Spain) was used for
the detection of the N protein.
IPMAs. Immunoperoxidase monolayer assays (IPMAs) were performed as
described previously (20). For the detection of the Gn and Gc proteins, a
polyclonal sheep antiserum was used (28).
Flow cytometry. Flow cytometry was performed using a CyAn ADP flow
cytometer (Beckman Coulter) equipped with a 488 nm laser. For the analysis of
the data, Summit v4.3 software was used.
Transmission electron microscopy (TEM). RRPs were applied to carbon-
coated copper Formvar grids (Stork Veco BV, Eerbeek, The Netherlands). The
grids were stained with 1% phosphotungstate (PTA) at pH 7 (Merck, Darmstadt,
Germany). Images were recorded at a calibrated magnification of 60,000 using
a FEI Tecnai 12 electron microscope.
VNTs using RRPs. Classical and RRP virus neutralization tests (VNTs) were
performed with sera from lambs that had previously been experimentally in-
fected with the 35/74 virus. To confirm the presence of RVFV-specific antibod-
ies, the sera were analyzed with a recombinant N (recN) RVFV enzyme-linked
immunosorbent assay (ELISA) (BDSL, Irvine, Ayrshire, Scotland, United King-
dom) prior to analysis by VNT. The classical VNT was performed as described
previously (20). For the RRP VNT, serum dilutions were prepared in 96-well
plates in 50 l GMEM supplemented with 5% FBS, 4% tryptose phosphate
broth (TPB), 1% MEM NEAA, and 1% penicillin-streptomycin. Culture me-
dium containing 200 RRPs in a 50-l volume was added to the serum dilutions
and incubated for 1.5 h at room temperature. Next, 50 l of growth medium
containing 40 000 BHK cells was added to each well. Plates were incubated at
37°C and 5% CO2. After 36 to 48 h, the neutralization titer was calculated by the
Spearman-Ka¨rber method (27, 41).
Vaccination and challenge of mice. Female BALB/c mice (Charles River
Laboratories, Maastricht, The Netherlands) were housed in groups of five ani-
mals and kept under biosafety level 3 containment. Groups of 10 mice were
vaccinated via the intramuscular or subcutaneous route either once, on day 21,
or twice, on days 0 and 21, with 106 TCID50 of RRPs in 50 l PBS. One group
of nine mice was left untreated. The body weights of the mice were monitored
weekly. On day 42, all mice were challenged via the intraperitoneal route with
102.7 TCID50 of RVFV strain 35/74 in 0.5 ml culture medium. Challenged mice
were monitored daily for visual signs of illness and mortality.
This experiment was approved by the Ethics Committee for Animal Experi-
ments of the Central Veterinary Institute of Wageningen University and Re-
search Centre.
RESULTS
Establishment of a three-plasmid system for the production
of RRPs. RVFV strain 35/74 was readily rescued from cDNA
by transfection of BSR-T7/5 cells with plasmids pUC57-S,
pUC57-M, and pUC57-L encoding the viral RNA segments in
antigenomic orientation. Our next aim was to produce only the
L and S genome segments and to package these segments into
RRPs by providing the structural glycoproteins Gn and Gc in
trans from a protein expression plasmid. To facilitate monitor-
ing of genome replication, a reporter minigenome was pro-
duced in which the nonessential NSs gene of the S genome
segment is replaced by the enhanced green fluorescent protein
(eGFP) gene (Fig. 1, inset). The resulting plasmid was named
pUC57-S-eGFP. Cotransfection of pUC57-L and pUC57-S-
eGFP into BSR-T7/5 cells resulted in only very few eGFP-
positive cells, and cotransfection with a plasmid providing the
NSm, Gn, and Gc proteins (i.e., pCAGGS-M) did not result in
the production of RRPs.
To improve the system, we evaluated the use of a recombi-
nant fowlpox virus as a source of T7 polymerase (15, 18). The
pUC57-S plasmid was transfected on its own into BSR-T7/5
cells and into BHK cells that had been infected with FP-T7
prior to transfection. Whereas the N protein was not detected
in BSR-T7/5 cells transfected with pUC57-S, FP-T7-infected
BHK cells that were transfected with this plasmid stained in-
tensely with a monoclonal antibody (MAb) specific for the N
protein (Fig. 2).
BHK cells were infected with the fowlpox virus (FP-T7) and
subsequently transfected with pUC57-S-eGFP only, cotrans-
fected with pUC57-S-eGFP and pUC57-L, or cotransfected
with pUC57-S-eGFP, pUC57-L, and pCAGGS-M. Transfec-
tion with only pUC57-S-eGFP did not result in eGFP expres-
sion (Fig. 3A). After 72 h, eGFP expression was observed in a
small percentage (0.33%) of cells that were cotransfected with
pUC57-S-eGFP and pUC57-L. However, when pCAGGS-M
was added to the transfection mixture, about one quarter of
the cells expressed eGFP (Fig. 3A). This finding suggested that
infectious particles were formed upon introduction of the
pCAGGS-M plasmid, resulting in an increase in the number of
eGFP-expressing cells. Collected supernatant was added to
BHK cell monolayers, and after 36 h, infection was monitored
by fluorescence microscopy. Only cells incubated with the su-
pernatant obtained from cells transfected with all three plas-
mids exhibited eGFP expression. This confirmed that we were
successful in producing RVFV replicon particles (RRPs).
Three independently performed experiments yielded an av-
erage RRP titer of 104.8 TCID50/ml. The three-plasmid sys-
FIG. 2. Expression of the N protein from the antigenomic-sense S
segment. BSR-T7/5 cells (A) or FP-T7-infected BHK-21 cells (B) were
transfected with plasmid pUC57-S, containing the RVFV S genome
segment in antigenomic-sense orientation. Expression of the RVFV N
protein was detected using an N-protein-specific MAb and horseradish
peroxidase-conjugated anti-mouse IgG antibodies.
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tem for the production of RRPs is schematically depicted in
Fig. 3B.
Establishment of a one-plasmid system for the production
of RRPs. The RRP titers obtained with the three-plasmid sys-
tem never exceeded 105 TCID50/ml. To develop a system for
the continuous production of high-titer RRPs, we created sta-
ble BHK cell lines that constitutively produce the Gn and Gc
proteins. BHK cells were transfected with pCIneo-GnGc, and
clones with integrated plasmids were grown in the presence of
G-418. Whereas an anti-Gn/Gc serum revealed clear glycopro-
tein expression 1 to 2 days after transfection, after cloning of
the cells, only very few selected clones revealed Gn/Gc expres-
sion by IPMA, and in all cases, expression seemed very low.
One clone that revealed the most intense staining in IPMAs
(Fig. 4) was selected and named BHK-GnGc.
It was previously demonstrated that expression of the Gn
and Gc proteins in both mammalian (31) and insect cells (20)
results in the production of VLPs. To determine if VLPs were
produced by BHK-GnGc cells, supernatants were ultracentri-
fuged (100,000  g, 2 h), and the proteins in the collected
pellets were analyzed by Western blotting. Neither the Gn nor
the Gc protein was detected in the pellet fractions (data not
shown), suggesting either that no VLPs were produced or,
more likely, that glycoprotein production was too low to allow
detection.
Although the BHK-GnGc cells apparently produced only
very limited amounts of Gn and Gc, we hypothesized that these
cells might tolerate Gn/Gc expression from plasmids to a
greater extent than normal BHK cells and therefore be more
suitable for RRP production. To substantiate this hypothesis,
BHK-GnGc cells were infected with FP-T7 and subsequently
cotransfected with the three plasmids. In an attempt to in-
crease the number of eGFP-expressing cells, the cells were
next transfected with pCAGGS-M only. This whole procedure
was then repeated, followed by two cell passages and introduc-
tion of the pCAGGS-M plasmid (Fig. 5A). At this point, flow
cytometry demonstrated that 90% of the BHK-GnGc cells
were positive for eGFP expression. The resulting cell line,
which maintains the L genome segment and the S-eGFP mini-
genome, was designated BHK-Rep. Transfection of BHK-Rep
cells with pCAGGS-M after cell passages 83, 103, and 105
yielded an average RRP titer of 106.7 TCID50/ml. It is impor-
tant to note that we also used a similar protocol starting with
wild-type BHK cells instead of BHK-GnGc cells. In these ex-
periments, reporter gene expression did not continue to in-
crease, and we were therefore unable to produce a cell line
with 90% reporter gene expression using this procedure.
The NSm protein was previously reported to suppress virus-
induced apoptosis (45), so we reasoned that a cell line consti-
tutively expressing not only Gn and Gc but also the NSm
proteins could be more efficient in the constitutive production
of RRPs by suppressing apoptosis. To this end, we aimed to
produce a BHK-Rep cell line with a stably integrated plasmid
encoding the NSm, Gn, and Gc proteins (i.e., pCIneo-M). For
convenience, the L and S-eGFP genome segments were
introduced into BHK cells not by transfection of plasmids
but instead by infection of the cells with RRPs combined
with transfection with pCAGGS-M. Cells were passaged and
subsequently transfected with pCIneo-M and grown in the
presence of G-418. In this way, BHK-Rep cells were produced
FIG. 3. Production of RRPs by the three-plasmid system. (A) BHK cells were infected with FP-T7 and subsequently remained untreated
(mock) or were transfected with plasmid pUC57-S-eGFP (S-eGFP) only, in combination with plasmid pUC57-L encoding the RVFV L genome
segment (S-eGFP/L), or with the aforementioned plasmids and pCAGGS-M (GP), encoding the structural glycoproteins (S-eGFP/L/GP). The
percentage of eGFP-positive cells was determined by flow cytometry (values are means and standard deviations for three replicates). (B) Schematic
representation of the three-plasmid system. BHK cells were first infected with FP-T7 (step 1) and subsequently transfected with transcription
plasmids pUC57-L (L) and pUC57-S-eGFP (S) and expression plasmid pCAGGS-M (step 2). After 24 h, the culture medium containing the RRPs
was collected (step 3). Transcription from the expression plasmid is controlled by a CAG promoter (CAGp), and transcription from the
transcription plasmids is controlled by a T7 promoter (T7p). Untranslated regions are depicted as black boxes.
FIG. 4. (A) RVFV glycoprotein expression in BHK-GnGc cells.
BHK cells were transfected with plasmid pCIneo-GnGc, encoding the
RVFV structural glycoproteins Gn and Gc. The BHK-GnGc cells were
cloned by limiting dilution. Expression of Gn and Gc was detected by
staining of BHK-GnGc cells with polyclonal antibodies specific for the
Gn and Gc proteins. (B) Similarly treated BHK parent cells.
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without introducing FP-T7 and the transcription plasmids. The
cells were used for cloning by endpoint dilution, and a selected
clone was named BHK-Rep2. The steps followed to produce
the BHK-Rep2 cell line are depicted in Fig. 5B. Although this
cell line also did not constitutively produce RRPs, transfection
of this cell line with the pCAGGS-M plasmid yielded an aver-
age RRP titer of 107.2 TCID50/ml (n  6).
To determine if other mammalian and insect cells can be
infected with RRPs, human embryonic kidney 293 cells
(HEK293T), Drosophila S2 cells, and Aedes albopictus C6/36
cells were infected with RRPs at an MOI of 1 (calculated using
the titer determined on BHK cells). This experiment demon-
strated that both mammalian and insect cells can be readily
infected with RRPs (Fig. 6). Expression of eGFP in mamma-
lian cells and insect cells was optimal at 42 and 72 h postin-
fection, respectively.
It is important to note that the one-plasmid system is not
restricted to BHK-Rep cells. Transfection of RRP-infected
HEK293T cells with the pCAGGS-M plasmid yielded an RRP
titer of 106.5 TCID50/ml. This demonstrates that alternative
cell types can be used for the production of RRPs by combin-
ing an RRP infection with a transfection of the pCAGGS-M
plasmid (Fig. 7).
Characterization of BHK-Rep cells. Persistence of RVFV
RNA in cells was previously reported by Billecocq et al. (6).
Those authors detected defective interfering (DI) RNAs with
large internal deletions and suggested that these DI RNAs
could be responsible for the persistent infection. Considering
this, we determined whether abnormal viral RNA segments
were present in the BHK-Rep and BHK-Rep2 cells. Northern
blotting was performed with total RNA extracted from BHK-
Rep and BHK-Rep2 cells at cell passage 13 and 45, respec-
tively. S-, M-, and L-specific probes revealed only the S and L
segments, confirming that no M segment is present in the
BHK-Rep cells (Fig. 8). The S-eGFP and L segments were
detected at the same positions as the S and L segments of the
recombinant virus, suggesting that no significant levels of DI
RNAs were present.
To determine if mutations were introduced upon replication
of the L and S-eGFP genome segments in BHK-Rep cells,
cDNA was produced and sequenced, with the exception of the
primer binding regions on the extreme 3 and 5 ends, using
standard techniques. Only a single mutation (G11813A) was
detected in the L genome segment present in the BHK-Rep
FIG. 5. Cartoon representing the construction of the BHK-Rep (A) and BHK-Rep2 (B) cell lines. Construction of the BHK-Rep cells started
with a BHK cell line constitutively expressing small amounts of the Gn and Gc proteins (BHK-GnGc), whereas wild-type BHK cells were used for
production of the BHK-Rep2 cell line. Stable glycoprotein expression was achieved in these cells by introducing the pCIneo-M plasmid. The
S-eGFP and L genome segments were introduced in the BHK-Rep cell line by FP-T7-driven transcription from plasmids, whereas these genome
segments were introduced into the BHK-Rep2 cells by infection with RRPs. Transfection with pCAGGS-M was used to produce RRPs, which
assist in spread of the genome segments among cells.
FIG. 6. RRP infection of mammalian cells (A) and insect cells (B).
BHK cells, human embryonic kidney 293T cells (HEK293T), Drosoph-
ila S2 cells, and Aedes albopictus C6/36 cells were infected with RRPs
at an MOI of 1. The number of positive cells was determined by flow
cytometry at 42 (BHK and HEK293T) or 72 (S2 and C6/36) h postin-
fection. Histograms show averaged results of three independent mea-
surements, with standard deviations.
FIG. 7. Schematic representation of the one-plasmid systems.
Transfection of BHK-Rep cells with pCAGGS-M results in the pro-
duction of RRPs. Alternatively, RRPs can be produced by infection of
potentially any type of mammalian cell, such as HEK293T cells, by
infection with RRPs followed by transfection with pCAGGS-M.
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cells, resulting in an amino acid change from glycine to glu-
tamic acid at position 388 of the L protein. This mutation was
also detected in the BHK-Rep2 cells, together with a silent
mutation in the L gene (A16023C) and two mutations in the
5 untranslated region (T63253C and T63673C). In the S-
eGFP segments, only a single silent mutation was detected in
the BHK-Rep2 cells (C653T). The number of the mutations
corresponds to their position in the antigenomic-sense RNA.
We did not study the effect of these mutations further.
The viral RNA segments were introduced in BHK-Rep cells
by plasmids that were transcribed by the FP-T7 virus. Although
it is well established that FPV does not replicate in mammalian
cells (15), the BHK-Rep and BHK-Rep2 cells were tested for
the presence of FP-T7 by PCR. No FPV DNA was detected in
these assays (data not shown).
Characterization of RRPs. To establish the kinetics of RRP
production, BHK-rep cells were transfected with pCAGGS-M,
and the culture medium was collected at different time points
posttransfection. This experiment demonstrated that the titer
was already close to 106 TCID50/ml after 22 h (Fig. 9A).
To demonstrate that RRPs are incapable of autonomous
spread, BHK cells were infected with RRPs at an MOI of 1.
After 2 days, eGFP expression was observed by fluorescence
microscopy (Fig. 9B, left). BHK cells were incubated with the
collected precleared supernatant, and after 3 days, cells were
monitored for eGFP expression. No eGFP expression was ob-
served, demonstrating that no progeny infectious particles
were produced by the RRP-infected BHK cells (Fig. 9B, right).
To visualize RRPs by transmission electron microscopy
(TEM), BHK-Rep2 cells were transfected with pCAGGS-M.
After 30 h, the RRPs present in precleared culture supernatant
were concentrated using Amicon filters and subsequently used
to coat carbon-coated Formvar grids. Grids were stained with
FIG. 8. Northern blot analysis of the viral RNA segments present
in BHK-Rep cells. Total RNA of BHK-Rep and BHK-Rep2 cells was
extracted, separated by electrophoresis using the glyoxal-dimethyl sul-
foxide system, and transferred to positively charged nylon membranes.
Hybridization was performed with DIG-labeled S, M, and L probes,
and hybridization was detected by phosphatase-conjugated anti-DIG
antibodies. RNA extracted from recombinant RVFV 35/74 was used as
a positive control and a reference for size. Wild-type BHK cells were
used as a negative control. The specificity of the probe used for hy-
bridization of each blot is indicated below each panel. The positions of
the S, M, and L segments are indicated by arrows.
FIG. 9. Characterization of RRPs. (A) BHK-Rep cells were either left untreated (GP) or transfected with pCAGGS-M (GP), and RRP
titers in the collected supernatant were determined at different time points posttransfection. (B) To demonstrate that RRPs are nonspreading,
BHK cells were infected with RRPs, and after 2 days, eGFP expression was observed in infected cells (left). Fresh BHK cells were incubated with
the collected supernatant and monitored for eGFP expression after 3 days (right). (C) Electron micrograph of RRPs. Concentrated RRPs were
stained with 1% PTA and analyzed by TEM. Bar, 50 nm. (D) To visualize RRP proteins, culture medium of BHK-Rep cells (GP) or of BHK-Rep
cells transfected with pCAGGS-M (GP) was ultracentrifuged at 100,000  g for 2 h. The proteins present in the pellets were separated in 4 to
12% bis-Tris gels and subsequently transferred to nitrocellulose blots. Specific proteins were detected by an anti-Gn (	 Gn) or anti-Gc (	 Gc)
peptide antiserum or a MAb specific for the N protein (	 N). The positions of the NSm, Gn, Gc, and N proteins are indicated by arrows. Molecular
weight standards are indicated on the right, in thousands.
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1% PTA and analyzed by TEM. Representative particles of
80 
 2 nm are depicted in Fig. 9C. The average particle size
varied from 80 to 100 nm.
To visualize RRP proteins, RRPs were pelleted by ultracen-
trifugation. The proteins were separated in polyacrylamide
gels, transferred to nitrocellulose membranes, and detected
using peptide antisera specific for the Gn and Gc proteins or a
MAb specific for the N protein. Analysis of the supernatant
obtained from nontransfected BHK-Rep cells revealed only
the N protein (Fig. 9D). This result suggests that the RVFV N
protein is released from cells, resembling results previously
obtained in studies on CCHFV (4). Analysis of supernatant
from BHK-Rep cells transfected with pCAGGS-M revealed
the NSm1 protein, the Gn and Gc proteins, and the N protein
(Fig. 9D).
Establishment of a novel VNT. To determine if RRPs can be
used in VNTs, sera obtained from experimentally infected
lambs were used in the classical VNT as described previously
(20) and used in a novel VNT that uses RRPs instead of live
virus. The sera were also tested by ELISA. As is done with the
complete virus in the classical VNT, serum dilutions were
preincubated with RRPs, and the mixtures were subsequently
incubated with BHK cells. Whereas in the classical VNT, the
lack of neutralization is detected by cytopathic effect, in the
RRP VNT, eGFP expression demonstrates lack of neutraliza-
tion. Titers are determined in both assays using the Spearman-
Ka¨rber method (27, 41).
The experiment revealed that the so-called RRP VNT has
an optimal readout between 36 and 48 h and has a sensitivity
equal to, if not higher than, that of the classical VNT (Table 1).
Vaccination and challenge of mice. To study the vaccine
efficacy of RRPs, groups of 10 mice were immunized with 50 l
of an inoculum containing 106 TCID50 of RRPs, via either the
subcutaneous or intramuscular route, either once or twice with
a 3-week interval. One group of 9 nonvaccinated mice was
added as a control group. The mice were challenged on day 42
with a known lethal dose of RVFV strain 35/74. All nonvacci-
nated mice displayed overt clinical signs and weight loss, and
eight of a total of nine nonvaccinated mice succumbed to the
infection within 4 days after challenge. One mouse survived for
12 days but eventually died. The survival rate in the groups of
mice vaccinated either once or twice via the subcutaneous
route was 60%. In contrast, 100% of the mice vaccinated via
the intramuscular route, either once or twice, survived the
challenge (Fig. 10). These mice did not show any clinical signs
or weight loss throughout the experiment. This demonstrates
that a single intramuscular vaccination with 106 RRPs can
protect mice from a lethal dose of RVFV.
DISCUSSION
Here, we report the creation of a nonspreading bunyavirus.
Critical to the production of the RVFV replicon particles
(RRPs) was the use of FPV as a source of T7 polymerase.
Despite much effort, production of RRPs using BSR-T7/5
cells, which are routinely used for bunyavirus reverse genetics,
never succeeded.
Rescue of a bunyavirus requires only three T7 transcripts
representing the viral RNA molecules in antigenomic-sense
orientation. This suggests that the antigenomes act not only as
replication intermediates but also as mRNAs (30). Although in
our experiments, expression of the N protein from antigenom-
ic-sense S RNA was not detectable in BSR-T7/5 cells, expres-
sion was readily detected in FP-T7-infected cells. T7-based
transcription in BSR-T7/5 cells results in uncapped RNAs,
whereas the FP-T7 virus provides its own capping enzyme (15).
We propose that this explains the improved gene expression
from antigenomic viral RNAs and thereby the superiority of
FP-T7-infected cells over BSR-T7/5 cells to drive minigenome
expression.
It is interesting that the first rescue of a bunyavirus (i.e.,
Bunyamwera virus [BUNV]) from cDNA was performed using
another poxvirus, namely, vaccinia virus (VV), as a source of
T7 polymerase (i.e., vTF7-3) (14). The protocol for BUNV
rescue was later adapted to use BSR-T7/5 cells, which circum-
vented the need to remove the VV from the culture medium
after bunyavirus rescue (30). In our studies, we preferred FPV
over VV for providing T7 polymerase, since the former not
only is much less cytopathic but also does not replicate in
mammalian cells (15). There is thus no FPV to be removed
from the culture medium after rescue of a bunyavirus.
Although production of RRPs using the initially established
three-plasmid system is highly reproducible, yields of RRPs
using this system never exceeded 105 TCID50/ml. We therefore
FIG. 10. Vaccine efficacy of RRPs. Mice were either left unvacci-
nated (n  9; mock) or vaccinated (n  10) either once (1) or twice
(2) via the intramuscular route (IM) or subcutaneous route (SC)
with 106 TCID50 of RRPs. Mice were challenged with a known lethal
dose of RVFV strain 35/74 via the intraperitoneal route. The mortality
rates were determined until 21 days postchallenge (d.p.c.).
TABLE 1. Comparison of classical VNT and RRP VNT
Serum sample
Neutralization titer
in VNTa ELISA resultb
Classical RRP
4308 3.56 3.94 Pos
4309 4.09 4.16 Pos
4310 0 0 Neg
4311 4.01 4.24 Pos
4312 3.71 4.76 Pos
4314 3.56 4.46 Pos
4315 3.71 4.39 Pos
4318 4.16 4.39 Pos
4321 0 0 Neg
4324 4.24 4.31 Pos
4328 4.01 4.69 Pos
a Reported as log10 50% endpoint titers.
b Sera were analyzed by the recN ELISA (BDSL).
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aimed to develop a system that allows the constitutive produc-
tion of higher titers of RRPs. Stable cell lines were created that
constitutively produce the structural glycoproteins Gn and Gc,
but the levels of expression were too low for efficient trans-
complementation. However, it was remarkable to find that
repeated passage of these cells when containing replicating L
and S-eGFP genome segments did not result in cytopathic
effect or loss of reporter gene expression. Reporter gene ex-
pression in the resulting BHK-Rep cells was maintained for at
least 100 cell passages. Importantly, when the RVFV genome
segments were introduced into wild-type BHK cells, expression
of the reporter was quickly lost upon passage of the cells.
Analysis of the culture medium of BHK-Rep cells was occa-
sionally found to contain low titers of RRPs, varying from
undetectable levels to 100 TCID50/ml. From this, we first hy-
pothesized that the small amounts of Gn and Gc endogenously
produced by the BHK-Rep cells ensures that cells that lose the
genome segments are reinfected with RRPs, thereby reintro-
ducing these segments. This hypothesis, however, was rejected,
since passage of the BHK-Rep cells in the presence of a neu-
tralizing serum did not result in a decrease in the number of
eGFP-positive cells (data not shown). It therefore remains
unclear at this point how BHK-Rep cells efficiently maintain
the RVFV genome segments.
By establishing the BHK-Rep cells, a one-plasmid system for
the production of RRPs was provided that can reproducibly
yield titers of up to 107 TCID50/ml even after 100 cell passages.
We also demonstrate that the one-plasmid system is not re-
stricted to using BHK-Rep cells. When combining an infection
with RRPs with a transfection of the plasmid encoding the
structural glycoproteins, any mammalian or insect cell can po-
tentially be used for the production of RRPs and the use of
FP-T7 and the transcription plasmids is no longer required. To
underscore this notion, we show that HEK293T cells can be
used for the efficient production of RRPs.
The VNT is the gold-standard diagnostic assay for the sero-
logic confirmation of RVFV infection and the prescribed test
for animal trade (36a). The classical VNT requires handling of
live RVFV and must therefore be performed in appropriate
biosafety containment facilities. Another drawback of the clas-
sical VNT is that the assay requires 5 to 7 days for completion.
We show that eGFP-expressing RRPs can be used for VNTs
that do not require biocontainment facilities and that this so-
called RRP-VNT requires only 24 to 48 h for completion.
Apart from the RRPs developed in the current work, attenu-
ated viruses containing the eGFP gene can potentially be sim-
ilarly applied.
Finally, we demonstrate that RRPs can be used as a highly
effective vaccine. We and others have previously reported ef-
ficient VLP production systems and VLPs comprising only the
Gn and Gc proteins are highly effective vaccine candidates (20,
29, 31, 32, 35, 38). Mandell et al. demonstrated that including
the N protein in VLPs improves vaccine efficacy (31), which
could be due to stabilization of the particle and/or to partial
protective efficacy mediated by the N protein alone (11). It was
subsequently reported that so-called infectious VLPs capable
of primary transcription of the N gene are remarkably effec-
tive, providing complete protection in mice after a single vac-
cination (38). The RRPs produced in the current work could
be even more efficacious, since the particles are capable of
autonomous genome replication and high-level gene expres-
sion. Replication of the RRP genome in vivo could induce
interferon and other innate immune responses and in vivo
production of the L and N proteins could also induce adaptive
cellular immune responses. Although additional studies are
required to characterize in detail the innate and adaptive im-
mune responses elicited by RRPs, we already demonstrate
here that a single intramuscular vaccination with RRPs pro-
tects mice against a lethal challenge dose. Experiments are
planned to study the immune response elicited by RRP vacci-
nation in detail and to study the vaccine efficacy of RRPs in
sheep.
Apart from applied research, our methods will also facilitate
studies on RVFV genome replication and packaging. In this
respect, it is interesting that the current work already demon-
strates that the M genome segment is not required for pack-
aging of the L segment, contrasting a recent suggestion (42).
Our system is also particularly useful for functional studies on
the structural glycoproteins Gn and Gc. Mutations can be
easily introduced in the pCAGGS-M plasmid, and their effects
on host cell attachment, entry, and fusion can be studied in-
dependently. Since the system does not depend on live virus,
even the nature of lethal mutations can be studied. An alter-
native system that can be used for such studies is the previously
described system for producing iVLPs (24, 38, 39). Reporter
gene expression in iVLP-infected cells, however, requires
cotransfection with helper plasmids, which likely renders this
system more prone to experimental variation than the one-
plasmid system described here.
In summary, the methods reported here allow both funda-
mental and applied research on RVFV to be conducted out-
side biocontainment facilities and will therefore greatly facili-
tate the development of novel therapeutics and vaccines for
the control of RVFV. A newly identified member of the
phlebovirus genus causing severe fever with thrombocyto-
penia syndrome (SFTS) in humans recently emerged in
China (46), and members of other genera of the bunyavirus
family, such as CCHFV and HTNV, also continue to be of
serious public health concern. The methods described here
could facilitate the future control of these highly pathogenic
bunyaviruses as well.
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